SIRT3

CCM Biosciences Announces Launch of Protein Upregulation Business Unit

Retrieved on: 
Wednesday, September 20, 2023
Medicinal chemistry, National academy, SIRT1, University, Chemical physics, Mitochondrion, Bioorganic & Medicinal Chemistry, Enzyme, NAD, Mutation, RNA, Infertility, Cystic fibrosis, SIRT3, Alzheimer's disease, University of Palermo, Parkinson's disease, Protein, CCM, Publication, Journal, Patient, PLOS, Biophysics, Fertility, The Journal of Chemical Physics, Regulation, Cystic Fibrosis Foundation, Physics, Longevity, Notifiable disease, IND, Gene, Sirtuin, Library, Messenger, Dietary supplement, Pharmaceutical industry, Vaccine

MOUNT LAUREL, N.J., Sept. 20, 2023 /PRNewswire/ -- CCM Biosciences, a pharmaceutical discovery and development company that recently confirmed its launch from stealth, today announced its latest business unit — CCM Protein Upregulation — dedicated to advancing first-in-class drug leads for age-related conditions such as Alzheimer's, Parkinson's, and infertility as well as for genetically inherited diseases such as cystic fibrosis, using highly differentiated technology platforms for improving the enzymatic activity or expression level of critical proteins implicated in the pathogenesis of such disorders. 

Key Points: 
  • New business unit is focused on "undruggable" targets for age-related indications and genetically inherited diseases.
  • Enhancement of the activity or expression level of proteins is important for the treatment of many age-related and genetically inherited conditions.
  • Such compounds have the potential to rejuvenate the activity of SIRT3 to levels observed in youth," said Dr. Raj Chakrabarti, CEO of CCM Biosciences.
  • CCM Protein Upregulation's drug leads represent a first-in-class opportunity to treat multiple diseases caused by nonsense mutations.

Elysium Health™ Announces the Launch of SIGNAL™ for Metabolic Aging

Retrieved on: 
Tuesday, January 25, 2022
Elysium, Research, Imai, NAD, Ageing, Sport, Sirtuin 3, Mitochondrion, Overalls, Das, Elysium Health, International Society, Liao, Enzyme, Science, ATP, VO2, Biology, Metabolism, Health, Animal, SIGNAL, Tissue, Sirtuin, Fasting, NMN, Efficiency, Nicotinamide mononucleotide, ALS, Environment, MIT, Multimedia, Life, Cell, Calorie, Partnership, Amyotrophic lateral sclerosis, Pharmaceutical industry, Signal, SIRT3

"At Elysium Health, we recognize that aging is a multi-factor problem that requires a multi-factor solution," said Elysium Health CEO Eric Marcotulli.

Key Points: 
  • "At Elysium Health, we recognize that aging is a multi-factor problem that requires a multi-factor solution," said Elysium Health CEO Eric Marcotulli.
  • "With each new product we get closer to addressing aging holistically, and to offering our customers the opportunity to truly personalize their Elysium Health regimen.
  • The launch of Signal marks the fifth consumer product for Elysium Health since the brand launched in early 2015.
  • Working directly with the world's leading scientists and clinicians, Elysium Health is committed to translating critical advancements in aging research into health solutions people can access today.